← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Omvax, Inc.
San Francisco, CA
$5,087,569
Total funding
3
Grants
Funding over time
peak $1.4M · FY2016–24$2M$1.5M$1M$500K$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,087,569 · 3
By mechanism
R44$3,000,000 · 1
R01$1,787,599 · 1
R41$299,970 · 1
Investigators at Omvax, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups$1,000,000
R44 · FY2022 · AI
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups$1,000,000
R44 · FY2021 · AI
A next-generation meningococcal serogroup B vaccine with improved effectiveness for all age groups$1,000,000
R44 · FY2020 · AI
Meningococcal and gonococcal vaccine to prevent invasive disease and carriage$373,730
R01 · FY2024 · AI
Meningococcal and gonococcal vaccine to prevent invasive disease and carriage$373,730
R01 · FY2022 · AI
Meningococcal and gonococcal vaccine to prevent invasive disease and carriage$373,730
R01 · FY2021 · AI
Meningococcal and gonococcal vaccine to prevent invasive disease and carriage$373,730
R01 · FY2023 · AI
A universal vaccine for the prevention of meningococcal meningitis in Africa$299,970
R41 · FY2016 · AI
Meningococcal and gonococcal vaccine to prevent invasive disease and carriage$292,679
R01 · FY2020 · AI